Status:
COMPLETED
ASYMPTOMATIC CARRIER OF LEISHMANIA INFANTUM, MEDISERRANEAN VISCERAL LEISHMANIOSIS AGENT: STUDY OF IMMUNE RESPONSE -
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Leishmaniasis, Cutaneous
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
Leishmaniasis is considered by the WHO as emerging and uncontrolled diseases. They are the second leading cause of death and the fourth leading cause of morbidity in tropical diseases. Leishmaniasis i...
Eligibility Criteria
Inclusion
- Inclusion Criteria for asymptomatic careers
- Male and Female
- Age between 18 and 80 years
- PCR and western blot positive to L. Infantum (these exams will be redone as part of the study).
- Signature of informed consent
- Affiliation to a social security scheme
- Exclusion Criteria:
- Presence of known immunosuppression or immunosuppressive therapy. -HIV-positive people will be excluded because of the immunosuppressive action of HIV on the immune system. HIV status will be determined by interrogation.
- Pregnant women will be excluded. A urinary pregnancy test (taken from the inclusion proposal) will be performed for women of child-bearing age. The results will be communicated to the patient by a doctor of her choice.
- Persons under guardianship
- Inclusion Criteria for healthy patient
- Male or Female
- Age between 18 and 80 years
- PCR and western blot negative Leishmania (these exams will be redone as part of the study).
- Signature of informed consent
- Affiliation to a social security scheme
- Exclusion Criteria:
- Presence of known immunosuppression or immunosuppressive therapy. -HIV-positive people will be excluded because of the immunosuppressive action of HIV on the immune system. HIV status will be determined by interrogation.
- Pregnant women will be excluded. A urinary pregnancy test (taken from the inclusion proposal) will be performed for women of child-bearing age. The results will be communicated to the patient by a doctor of her choice.
Exclusion
Key Trial Info
Start Date :
November 10 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2021
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03303898
Start Date
November 10 2017
End Date
September 1 2021
Last Update
March 18 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nice Hospital
Nice, France, 06000